On Monday, Shares of Endo International plc (NASDAQ:ENDP), dropped -2.82% to $90.64.
Endo International, will declare its first quarter 2015 financial results before the open of the U.S. financial markets on May 11, 2015 and members of its senior administration team will host a conference call and webcast at 9:00 a.m. ET that day.
The dial-in number to access the call is U.S./ Canada (866) 497-0462, International (678) 509-7598, and the conference number is 34236444. Please dial in 10 minutes preceding to the planned start time.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals.
Shares of Royal Caribbean Cruises Ltd. (NYSE:RCL), declined -2.77% to $70.46, during its last trading session.
Royal Caribbean Cruises, declared that Paul T. Parker has been named senior vice president and chief human resources officer. Parker joins Royal Caribbean with more than 20 years of experience implementing human resources strategies for leading brands counting Sabra Dipping Company, Deloitte & Touche, Colgate Palmolive, Campbell Soup and Nabisco Food Company. Parker will report directly to Adam Goldstein, president and COO of Royal Caribbean Cruises Ltd.
Parker most recently served as vice president and chief human resources officer for Sabra Dipping Company, where he established a market-based compensation system, revised the selection and onboarding process and reduced turnover by 50 percent while increasing employee engagement scores by 25 percent. Preceding to that, Parker was the senior client partner for BSG Partners. Throughout his career, he has held a variety of administration positions, counting chief people officer for Deloitte and vice president of human resources for Colgate Palmolive.
Parker graduated from New York University’s Leonard N. Stern School of Business with a MBA, and from Ithaca College with a B.S. in Human Resource Administration.
Royal Caribbean Cruises, Ltd. operates as a cruise company. The company operates cruisers under the Royal Caribbean International, Celebrity Cruises, Pullmantur, Azamara Club Cruises, CDF Croisières de France, and TUI Cruises brand names.
At the end of Monday’s trade, Shares of Southwest Airlines Co. (NYSE:LUV), dwindled -2.76% to $42.29.
Southwest Airlines, stated its first quarter 2015 results:
- Record first quarter net income, not taking into account special items, of $451 million, or $.66 per diluted share, contrast with first quarter 2014 net income, not taking into account special items, of $126 million, or $.18 per diluted share. This represented a 266.7 percent enhance from first quarter 2014 and exceeded the First Call consensus estimate of $.65 per diluted share.
- Record first quarter net income of $453 million, or $.66 per diluted share, which comprised of $2 million (net) of favorable special items, contrast with first quarter 2014 net income of $152 million, or $.22 per diluted share, which comprised of $26 million (net) of favorable special items.
- Record first quarter operating income of $780 million. Not taking into account special items, record first quarter operating income of $770 million, resulting in an operating margin of 17.4 percent.
- Strong free cash flow1 of $859 million used to return $381 million to Shareholders through dividends and share repurchases, and to repay $51 million in debt and capital lease obligations.
- Return on invested capital, before taxes and not taking into account special items (ROIC), for the 12 months ended March 31, 2015, of 25.6 percent, contrast with 14.2 percent for the 12 months ended March 31, 2014.
Southwest Airlines Co. operates passenger airlines that provide planned air transportation services in the United States and near-international markets. As of December 31, 2014, it operated 665 Boeing 737 aircraft; and had 12 Boeing 717 aircraft.
Finally, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), ended its last trade with -2.75% loss, and closed at $116.97.
BioMarin Pharmaceutical, declared completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for drisapersen, an investigational exon-skipping drug candidate for the treatment of the largest genetically defined subset of Duchenne muscular dystrophy (DMD). DMD is the most common fatal genetic disorder diagnosed in childhood, affecting about 1 in every 3,500 live male births with about 20,000 new cases diagnosed globally each year. Drisapersen induces the skipping of dystrophin exon 51, potentially providing a therapeutic benefit to DMD patients for whom skipping of exon 51 restores the proper dystrophin reading frame, corresponding to about 13% of DMD patients. The company intends to also submit an application for registration in the European Union in summer 2015.
Drisapersen has been granted Orphan and Fast Track status, in addition to Breakthrough Therapy designation by the FDA.
DMD is caused by a mutation in the gene that encodes for dystrophin, a protein that is important in connecting the cytoskeleton of muscle fibers to the extracellular matrix. Its deficiency in DMD leads to progressive muscle weakness, loss of ambulation in early adolescence, and typically death due to pulmonary or cardiac insufficiency in the late twenties. Because the Duchenne gene is found on the X-chromosome, it primarily affects boys; however, it occurs across all races and cultures. There is presently no approved therapy in the United States for DMD.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
